Clinical Trials

Genentech announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with…
Read More...

Concert Pharmaceuticals announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive…
Read More...

Ironwood Pharmaceuticals announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase…
Read More...

AbbVie announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung…
Read More...

CRISPR Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics…
Read More...

Genkyotex announced that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after…
Read More...

MaaT Pharma announced the dosing of the first patient in a Phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute…
Read More...

Bristol-Myers Squibb Company and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an…
Read More...

The first clinical trial of a completely novel and unprecedented approach to modifying the progression of Alzheimer's disease has opened in London. The study is being conducted in the…
Read More...

Innovent Biologics announced that its IND application for IBI-188, a fully human anti-CD47 monoclonal antibody (mAb) drug candidate, has been approved by the US Food & Drug…
Read More...

Selexis SA and Hoba Therapeutics announced that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of…
Read More...

Sarepta Therapeutics announced that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy…
Read More...

Gilead Sciences and Galapagos announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary…
Read More...

Thrombolytic Science, LLC (TSI) announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue…
Read More...

SGS announced that it has successfully implemented advanced techniques for the collection and use of Peripheral Blood Mononuclear Cells (PBMCs) for early phase clinical trials at its…
Read More...

CRF Health announced that its TrialMax Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study. The large-scale trial will involve up to…
Read More...

PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is…
Read More...

Pfizer Inc. announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety…
Read More...

Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie, a research-based global biopharmaceutical company, exploring the potential of combination therapy…
Read More...